Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228-Reference-Cited by-同舟云学术

Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228

Published:2023-04 Issue:4 Volume:18 Page:516-526
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Paik Paul K.,Fan Pang-Dian,Qeriqi Besnik,Namakydoust Azadeh,Daly Bobby,Ahn Linda,Kim Rachel,Plodkowski Andrew,Ni Ai,Chang Jason,Fanaroff Rachel,Ladanyi Marc,de Stanchina Elisa,Rudin Charles M.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference30 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer;Paz-Ares;N Engl J Med,2018

3. A phase 1b open label multicentre study of AZD4547 in patients with advanced squamous cell lung cancers;Paik;Clin Cancer Res,2017

4. Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

5. A phase II study of GDC-0032 (taselisib) for previously treated PI3K positive patients with stage IV squamous cell lung cancer (SqNSCLC): LUNG-MAP sub-study SWOG S1400B;Wade;J Clin Oncol,2017

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DataXflow: Synergizing data-driven modeling with best parameter fit and optimal control – An efficient data analysis for cancer research;Computational and Structural Biotechnology Journal;2024-12

2. Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study;Clinical Genitourinary Cancer;2024-10

3. Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities;Trends in Pharmacological Sciences;2024-06

4. AURKA emerges as a vulnerable target for KEAP1-deficient non-small cell lung cancer by activation of asparagine synthesis;Cell Death & Disease;2024-03-23

5. The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant Cancers;Cancers;2024-01-19